医学
低蛋白血症
膜性肾病
内科学
胃肠病学
危险系数
入射(几何)
肌酐
置信区间
肾病
优势比
回顾性队列研究
队列研究
血清白蛋白
风险因素
免疫学
肾病综合征
白蛋白
肾病科
蛋白尿
累积发病率
肾脏疾病
队列
比例危险模型
前瞻性队列研究
抗体
蛋白尿
低风险
作者
Ayman Al Jurdi,Christopher El Mouhayyar,Karim M. Yatim,Orhan Efe,Saif A. Muhsin,Leonardo V. Riella,Reza Zonozi,Karen A. Laliberte,John L. Niles,Anushya Jeyabalan
标识
DOI:10.1093/joneph/aajag121
摘要
BACKGROUND: Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity, may be associated with a higher risk of thrombotic complications. METHODS: We conducted a multicenter retrospective cohort study of individuals with membranous nephropathy and serum albumin <2.5 g/dL and evaluated risk factors for first thrombotic events. RESULTS: Sixty-seven individuals met the inclusion criteria. Median serum creatinine was 1.2 mg/dL (Interquartile range [IQR] 0.9-1.6), median urine protein-to-creatinine ratio (UPCR) was 11.9 g/g (IQR 8.5-16.5), and median nadir serum albumin level was 1.9 g/dL (IQR 1.6-2.2). Twenty-four individuals (36%) received no thromboprophylaxis, 20 (30%) received prophylaxis with only antiplatelets, and 23 (34%) received anticoagulation prophylaxis. Thrombotic events occurred in 11 individuals (16%) with incidence rates of 0.11, 0.10, and 0.02 per person-year in the no prophylaxis, antiplatelet, and anticoagulation groups, respectively. In individuals with anti-PLA2R antibody-positive MN who did not receive anticoagulation thromboprophylaxis, higher anti-PLA2R antibody levels were associated with a higher risk of developing thrombotic complications (adjusted Hazard Ratio [HR] = 1.51 per 10 RU/mL increase in PLA2R, 95% Confidence Interval [CI]: 1.10-2.09, P = .012) after adjusting for serum albumin nadir and age. CONCLUSIONS: Higher anti-PLA2R antibody levels at the time of hypoalbuminemia are associated with a higher risk of thrombotic complications in individuals with anti-PLA2R-positive MN.
科研通智能强力驱动
Strongly Powered by AbleSci AI